Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04496687 · ClinicalTrials.gov registry record
International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
A clinical trial of Spontaneous Coronary Artery Dissection, sponsored by SCAD Alliance.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 20
- Study locations
NCT04496687: Recruiting study of Spontaneous Coronary Artery Dissection, sponsored by SCAD Alliance.
NCT04496687 is a study of Spontaneous Coronary Artery Dissection that is actively recruiting participants, run by SCAD Alliance. The registered enrollment target is 1,000 participants, above the 688-participant average among 5 other Spontaneous Coronary Artery Dissection trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04496687, a study of Spontaneous Coronary Artery Dissection, is actively recruiting participants, sponsored by SCAD Alliance.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its recurrence. This observational study will be prospective and retrospective in its recruitment and will collect clinical information to better understand the natural history and prognosis for SCAD.
Primary Outcome
Participant demographic, historical, clinical characteristics, and treatment data
Conditions Studied
Study Locations (20)
California
- Cedars Sinai - Los Angeles
- UCLA (University of California, Los Angeles) - Los Angeles
- Kaiser Permanente Northern California - San Francisco
Missouri
- St. Luke's Mid America - Kansas City
- Washington University - St Louis
New Hampshire
- Dartmouth-Hitchcock - Lebanon
- Catholic Medical Center - Manchester
New York
- Mount Sinai - New York
- Columbia University Medical Center - New York
Colorado
- University of Colorado - Aurora
Connecticut
- Hartford Hospital - Hartford
Florida
- University of South Florida - Tampa
Georgia
- Emory Healthcare System - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2019-03-08 |
| Est. Completion | 2025-12-31 |
What NCT04496687 shows while recruiting
NCT04496687 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 688-participant average among 5 other Spontaneous Coronary Artery Dissection trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Spontaneous Coronary Artery Dissection appearing as the primary indexed condition, and to 0 interventions.
NCT04496687 names 20 study sites across 15 states, led by California, Missouri, New Hampshire.
Frequently Asked Questions
What is clinical trial NCT04496687 about?
NCT04496687 is a clinical study titled "International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry". The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and ther...
What is the current status of trial NCT04496687?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2019-03-08. Estimated completion is 2025-12-31.
What conditions does trial NCT04496687 study?
This clinical trial studies the following conditions: Spontaneous Coronary Artery Dissection.
Who is sponsoring clinical trial NCT04496687?
This trial is sponsored by SCAD Alliance, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04496687 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spontaneous Coronary Artery Dissection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The "Virtual" Multicenter Spontaneous Coronary Artery Dissection (SCAD) Registry
RECRUITING
-
A Study of SCAD Using Stress Contrast Echocardiography
RECRUITING
-
Defining the Basis of Fibromuscular Dysplasia (FMD)
RECRUITING
-
A Study to Analyze the Role of Sympathetic Nervous System in Spontaneous Coronary Artery Dissection
RECRUITING · NA
-
Angiographic and Psychosocial Evaluation of Peripartum vs. Non: SCAD
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI